2024-31523. Draft Guidances Relating to Recommendations To Reduce the Risk of Transmission of Relevant Communicable Disease Agents and Diseases by Human Cells, Tissues, and Cellular and Tissue-Based Products; Draft Guidances for Industry; ...
Table 1—Three Draft Guidances Issued for Public Comment
Docket No. Draft guidance document title FDA-2022-D-0465 Recommendations to Reduce the Risk of Transmission of Hepatitis B Virus (HBV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Draft Guidance for Industry. FDA-2022-D-0466 Recommendations to Reduce the Risk of Transmission of Hepatitis C Virus (HCV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Draft Guidance for Industry. FDA-2022-D-0467 Recommendations to Reduce the Risk of Transmission of Human Immunodeficiency Virus (HIV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Draft Guidance for Industry.
Document Information
- Published:
- 01/07/2025
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice of availability.
- Document Number:
- 2024-31523
- Dates:
- Submit either electronic or written comments on the draft guidances by February 6, 2025 to ensure that the Agency considers your comment on these draft guidances before it begins work on the final versions of the guidances.
- Pages:
- 1164-1166 (3 pages)
- Docket Numbers:
- Docket No. FDA-2022-D-0465, FDA-2022-D-0466, and FDA-2022-D-0467
- PDF File:
- 2024-31523.pdf